Anti‐interleukin 5 for treating severe refractory vernal keratoconjunctivitis in children: Two cases.

This article explores the use of anti-IL5 therapy as a potential treatment option for severe refractory vernal keratoconjunctivitis (VKC) in children. VKC is a chronic inflammatory disease that primarily affects children and is often associated with other allergic conditions. The article presents two cases where children with severe VKC were successfully switched to anti-IL5 therapy after previous treatment failures. While the therapy showed some improvement in symptoms and inflammation, topical corticosteroids were still necessary. The article suggests that further research and clinical trials are needed to confirm the efficacy of anti-IL5 therapy for refractory VKC, and emphasizes the importance of personalized treatment approaches based on individual patient profiles. [Extracted from the article]